Presbia Flexivue Microlens™ Implanted in More Than 1,000 Patients Worldwide

Presbia PLC (NASDAQ: LENS), an ophthalmic medical device company and leader in near-vision restoration announced today that more than 1000 patients worldwide have been treated with the Presbia Flexivue Microlens™.

"We are very pleased to announce this significant milestone,” said Todd Cooper, President and CEO of Presbia. "As we expand the commercialization of our Microlens into additional countries around the world, we are thrilled by the feedback we are receiving from surgeons regarding their patients’ satisfaction in their post-surgery vision improvement.”

Dr. Wayne Crewe-Brown, Clinical Director of Crewe-Brown Vision, UK and the Optilase Laser Eye Clinic Group in Ireland, said, "I’ve performed more than 275 implants of the Presbia Flexivue Microlens, and my patients have reported dramatic improvement in their near vision and very high satisfaction in the quick procedure.”

The Presbia Flexivue Microlens is a revolutionary optical lens implant for treating presbyopia, the age-related loss of near vision. It’s now commercially expanding in the European and the Asia Pacific regions of the world.

Forward-Looking Statements

Information provided and statements contained in this press release that are not purely historical are forward-looking statements. Such forward-looking statements only speak as of the date of this press release and Presbia assumes no obligation to update the information included in this press release. Statements made in this press release that are forward-looking in nature may involve risks and uncertainties. Accordingly, readers are cautioned that any such forward-looking statements are not guarantees and are subject to certain risks, uncertainties and assumptions that are difficult to predict. Although Presbia believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Unless otherwise required by law, Presbia also disclaims any obligation to update its view of any such risks or uncertainties or to announce publicly the result of any revisions to the forward-looking statements made in this press release.

About Presbia

Presbia PLC (NASDAQ:LENS) is an ophthalmic device company that has developed and is currently marketing the presbyopia-correcting Presbia Flexivue Microlens™, a miniature lens that is implanted in a corneal pocket created by a femtosecond laser. The Presbia Flexivue Microlens™ has received a CE mark for the European Economic Area, allowing the lens to be marketed in over 30 countries across Europe. A staged pivotal U.S. clinical trial for the Presbia Flexivue Microlens™ commenced in 2014.

View source version on businesswire.com: http://www.businesswire.com/news/home/20150917005017/en/